| 40.89 Delayed Data As of 4:01pm ET |  -0.51 / -1.23%Today’s Change | 34.52 Today|||52-Week Range 42.36 | +15.28% Year-to-Date |
| Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe Nov 13 / Zacks.com - Paid Partner Content | Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates Nov 02 / Zacks.com - Paid Partner Content |
| Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer Nov 12 / Zacks.com - Paid Partner Content | Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus Nov 02 / Zacks.com - Paid Partner Content |
| Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ Nov 08 / Zacks.com - Paid Partner Content | Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View Nov 01 / Zacks.com - Paid Partner Content |
| Mylan (MYL) Earnings Beat, Revenues Miss Estimates in Q3 Nov 06 / Zacks.com - Paid Partner Content |
| Previous close | 41.40 |
| Today’s open | 40.89 |
| Day’s range | 40.73 - 41.21 |
| Volume | 2,414,749 |
| Average volume (3 months) | 2,580,040 |
| Market cap | $102.7B |
| Earnings growth (last year) | +59.84% |
| Earnings growth (this year) | -3.13% |
| Earnings growth (next 5 years) | +5.50% |
| Revenue growth (last year) | +3.58% |
| P/E ratio | 41.6 |
| Price/Sales | 2.25 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | -0.09 | -0.22% |
| SNYSanofi | +0.18 | +0.40% |
| LLYEli Lilly and Co | -2.02 | -1.80% |
| BMYBristol-Myers Squibb | 0.00 | 0.00% |
| Next reporting date | February 6, 2019 |
| EPS forecast (this quarter) | $0.67 |
| Annual revenue (last year) | $38.9B |
| Annual profit (last year) | $2.0B |
| Net profit margin | 5.08% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Simon Paul Dingemans |
Corporate headquarters Brentford, Greater London |
